Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes

Sepideh Zareparsi; Jeffrey Kaye; Richard Camicioli; Holly Grimslid; Barry Oken; Michael Litt; John Nutt; Thomas Bird; Gerard Schellenberg; Haydeh Payami

doi:10.1002/ana.410420417

Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes

Sepideh Zareparsi, Jeffrey Kaye, Richard Camicioli, Holly Grimslid, Barry Oken, Michael Litt, John Nutt, Thomas Bird, Gerard Schellenberg, Haydeh Payami

Neurology

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

Parkinson's disease (PD) patients often develop dementia, and Alzheimer's disease (AD) patients frequently develop parkinsonian signs. The apolipoprotein E ε4 allele is associated with increased risk and earlier onset of AD. We studied 137 unrelated white PD patients. Those with ε4 had the earliest onset (52.7 ± 9.8 years), ε3/ε3 patients had an intermediate onset (56.1 ± 11.1 years), and those with ε2 had the latest onset (59.1 ± 13.4 years). The age at onset distribution for ε4/ε- was significantly earlier than for ε3/ε3 and ε2/ε3. These preliminary results suggest that apolipoprotein E genotypes modulate the age at onset of PD.

Original language	English (US)
Pages (from-to)	655-658
Number of pages	4
Journal	Annals of Neurology
Volume	42
Issue number	4
DOIs	https://doi.org/10.1002/ana.410420417
State	Published - Oct 1997

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.410420417

Cite this

@article{7aea3ee330c54e50bf86fc0b530b0fa0,

title = "Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes",

abstract = "Parkinson's disease (PD) patients often develop dementia, and Alzheimer's disease (AD) patients frequently develop parkinsonian signs. The apolipoprotein E ε4 allele is associated with increased risk and earlier onset of AD. We studied 137 unrelated white PD patients. Those with ε4 had the earliest onset (52.7 ± 9.8 years), ε3/ε3 patients had an intermediate onset (56.1 ± 11.1 years), and those with ε2 had the latest onset (59.1 ± 13.4 years). The age at onset distribution for ε4/ε- was significantly earlier than for ε3/ε3 and ε2/ε3. These preliminary results suggest that apolipoprotein E genotypes modulate the age at onset of PD.",

author = "Sepideh Zareparsi and Jeffrey Kaye and Richard Camicioli and Holly Grimslid and Barry Oken and Michael Litt and John Nutt and Thomas Bird and Gerard Schellenberg and Haydeh Payami",

year = "1997",

month = oct,

doi = "10.1002/ana.410420417",

language = "English (US)",

volume = "42",

pages = "655--658",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes

AU - Zareparsi, Sepideh

AU - Kaye, Jeffrey

AU - Camicioli, Richard

AU - Grimslid, Holly

AU - Oken, Barry

AU - Litt, Michael

AU - Nutt, John

AU - Bird, Thomas

AU - Schellenberg, Gerard

AU - Payami, Haydeh

PY - 1997/10

Y1 - 1997/10

N2 - Parkinson's disease (PD) patients often develop dementia, and Alzheimer's disease (AD) patients frequently develop parkinsonian signs. The apolipoprotein E ε4 allele is associated with increased risk and earlier onset of AD. We studied 137 unrelated white PD patients. Those with ε4 had the earliest onset (52.7 ± 9.8 years), ε3/ε3 patients had an intermediate onset (56.1 ± 11.1 years), and those with ε2 had the latest onset (59.1 ± 13.4 years). The age at onset distribution for ε4/ε- was significantly earlier than for ε3/ε3 and ε2/ε3. These preliminary results suggest that apolipoprotein E genotypes modulate the age at onset of PD.

AB - Parkinson's disease (PD) patients often develop dementia, and Alzheimer's disease (AD) patients frequently develop parkinsonian signs. The apolipoprotein E ε4 allele is associated with increased risk and earlier onset of AD. We studied 137 unrelated white PD patients. Those with ε4 had the earliest onset (52.7 ± 9.8 years), ε3/ε3 patients had an intermediate onset (56.1 ± 11.1 years), and those with ε2 had the latest onset (59.1 ± 13.4 years). The age at onset distribution for ε4/ε- was significantly earlier than for ε3/ε3 and ε2/ε3. These preliminary results suggest that apolipoprotein E genotypes modulate the age at onset of PD.

UR - http://www.scopus.com/inward/record.url?scp=0030881644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030881644&partnerID=8YFLogxK

U2 - 10.1002/ana.410420417

DO - 10.1002/ana.410420417

M3 - Article

C2 - 9382478

AN - SCOPUS:0030881644

SN - 0364-5134

VL - 42

SP - 655

EP - 658

JO - Annals of Neurology

JF - Annals of Neurology

IS - 4

ER -

Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this